Perleux^® – Rejuvenating Mesogel

Hyaluronic acid in Perleux^® is a polysaccharide which primary function is to maintain proper tissue hydration, thanks to its intrinsic ability to bind large amounts of water. The viscoelastic and hydrating properties of HA, along with its capacity to preserve adequate water levels in the cutaneous tissues, help rehydrate the skin. Additionally, HA plays a key role within the extracellular matrix by creating physiological conditions that support the proliferation, migration, and organization of dermal cellular components. Consequently, hyaluronic acid also promotes collagen production. Moreover, Perleux^® injection delivers an optimal amount of HA directly to the treated tissue to counteract the cytotoxic effects of free radicals on fibroblasts and the underlying adipose compartments.

Perleux^® consists of 16 mg (H-HA) + 16 mg (L-HA)/ 1 mL physiological buffer solution.

Perleux^® is indicated for facial rejuvenation. It is particularly indicated for the treatment of the malar-zygomatic and submalar areas. Perleux^® acts through a corrective action of natural and induced cutaneous depressions which intervenes:

• In the physiological process of skin aging, the effects which include reduced skin hydration, the alteration of elastic fibers and collagen of the dermis, with loss of turgor and skin tone.
• In the dermal tissue repair process, in case of scars resulting from superficial cutaneous trauma (e.g., acne and chicken pox scars).

For a global treatment of the malar and sub-malar areas, it is recommended to identify 5 points on each side (Bio aesthetic points) for intradermal administration of Perleux^®:

1) Zygomatic protrusion
2) Nasal base
3) Tragus
4) Chin
5) Mandibular angle

Inject 0.2 mL of product with the bolus technique in the deep dermal/subcutaneous layers.

An initial cycle of two treatment sessions at 30 days intervals is recommended, followed, if necessary, by maintenance treatments every 2 months. However, it is suggested to evaluate the specific protocol according to patients’ degree of aging.

Two pre-filled syringes with 2 needles 30G x ½”; each syringe contains the following volume:
16 mg (H-HA) + 16 mg (L-HA) of hyaluronic acid sodium salt

• The slow release of L-HA from the HA hybrid complexes does not trigger the first inflammatory cytokines, making it very biocompatible.
• H-HA in Perleux^® provides a stable HA architecture in the dermis. It gives a lifting effect.
• Increased expression levels of type I and type III collagen in fibroblasts, and type IV and VII collagen in keratinocytes.
• Skin quality and hydration are both improved in the dermis and epidermis.
• Increased production of endogenous HA and elastin gives the skin a more youthful look.

• Store the product at 2-25°C.
• The content is fragile.
• Shelf life is 2 years, correctly preserved.

• The point of injection must be on healthy skin.
• Do not inject into inflamed areas.
• Avoid injection into areas with a permanent implant
• Do not inject intravenously into muscles, tendons, or mammary augmentation.
• Avoid injection into the upper eyelids.
• It is not recommended for patients with acute rheumatic fever.
• It is not recommended for patients with allergic complications and anaphylactic shock.
• Avoid using Perleux^® for patients with untreated epilepsy, patients prone to hypertrophic ulcers, patients with a history of sensitivity to hyaluronic acid and/or proteins in gram-positive bacteria (streptococci), and patients with porphyria.
• Avoid injecting Perleux^® in pregnant or lactating women.
• Avoid injecting Perleux^® in children.
• It must not be used in Conjunction with treatments such as laser resurfacing and medium-deep skin peeling.
• Inform the patients to avoid ultraviolet exposure (protect the treated area with total sun-block creams), exposure to very low/very high temperatures, sauna, and hot bath within two weeks after the injection.
• Inform the patients to avoid any makeup for 12 hours after the injection.
• Inform the patients to avoid aspirin, NSAIDs, anticoagulants, platelet aggregation inhibitors, and any substance that prolongs blood clotting, such as herbal supplements containing garlic or maidenhair, etc., one week before injection.